Loss of exclusivityMarch 2040latest FDA-listed patent expiry
CompanySTRONGBRIDGE DUBLIN LTD
Drug detail
Brand name
RECORLEV
Active ingredient
LEVOKETOCONAZOLE
Strength
150MG
Dosage form
TABLET
Route
ORAL
Modality
Small molecule
FDA approval
December 2021
Marketing status
RX
Listed patents
Patent
Expires
Type
12377096
March 2040
use U-4236
11278547
March 2040
use U-3282
11903940
March 2040
use U-3821
11020393
March 2040
use U-3282
9918984
May 2028
use U-3283
10517868
January 2026
use U-3283
10098877
January 2026
use U-3283
11478471
January 2026
use U-3283
10835530
January 2026
use U-3283
Regulatory exclusivity
Code
Expires
ODE-385
December 2028
NCE*
December 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.